134 related articles for article (PubMed ID: 20179959)
1. Effects of intravitreal bevacizumab treatment on proliferative retinopathy in a patient with cerebroretinal vasculopathy.
Kernt M; Gschwendtner A; Neubauer AS; Dichgans M; Haritoglou C
J Neurol; 2010 Jul; 257(7):1213-4. PubMed ID: 20179959
[No Abstract] [Full Text] [Related]
2. Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia.
Rishi P; Rishi E; Shroff D
Indian J Ophthalmol; 2009; 57(3):241-2. PubMed ID: 19384026
[No Abstract] [Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
4. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab.
Bennett JL; Thomas S; Olson JL; Mandava N
J Neuroophthalmol; 2007 Sep; 27(3):238-40. PubMed ID: 17895825
[No Abstract] [Full Text] [Related]
5. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
6. Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin).
Thew M
Clin Exp Optom; 2009 Jan; 92(1):34-7. PubMed ID: 19125745
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab with regression of subretinal neovascularization after intraocular foreign body trauma.
Chen TL; Sun MH; Lin KK; Lai CC; Chen KJ
J Trauma; 2010 Mar; 68(3):747. PubMed ID: 20220430
[No Abstract] [Full Text] [Related]
8. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A.
Mavrakanas N; Mendrinos E; Pournaras CJ; Salzmann J
Acta Ophthalmol; 2009 Nov; 87(8):930-2. PubMed ID: 19706015
[No Abstract] [Full Text] [Related]
9. Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration.
Mete A; Saygili O; Mete A; Bayram M; Bekir N
J Clin Ultrasound; 2010 Feb; 38(2):66-70. PubMed ID: 19953626
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization.
Arriola-Villalobos P; Donate-López J; Calvo-González C; Reche-Frutos J; Alejandre-Alba N; Díaz-Valle D
Acta Ophthalmol; 2008 Feb; 86(1):115-6. PubMed ID: 17680838
[No Abstract] [Full Text] [Related]
11. Intravitreal injection of bevacizumab in Eales disease.
Küçükerdönmez C; Akova YA; Yilmaz G
Ocul Immunol Inflamm; 2008; 16(1):63-5. PubMed ID: 18379947
[TBL] [Abstract][Full Text] [Related]
12. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
Avery RL
Retina; 2006 Mar; 26(3):352-4. PubMed ID: 16508438
[No Abstract] [Full Text] [Related]
13. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.
Quiroz-Mercado H; Ustariz-González O; Martinez-Castellanos MA; Covarrubias P; Dominguez F; Sanchez-Huerta V
Semin Ophthalmol; 2007; 22(2):109-25. PubMed ID: 17564934
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab: a word of caution.
Kumar N; Sebastian R; Harding S; Pearce I
Can J Ophthalmol; 2007 Oct; 42(5):760-1. PubMed ID: 17891210
[No Abstract] [Full Text] [Related]
15. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization.
Kurup S; Lew J; Byrnes G; Yeh S; Nussenblatt R; Levy-Clarke G
Acta Ophthalmol; 2009 May; 87(3):349-52. PubMed ID: 18513266
[TBL] [Abstract][Full Text] [Related]
16. [Intravitreal injection of bevacizumab (Avastin) for retinal angiomatous proliferation].
Amselem L; Díaz-Llopis M; Cervera E; García-Delpech S; Moratal-Peiro B; Palomares P
Arch Soc Esp Oftalmol; 2008 Jan; 83(1):53-6. PubMed ID: 18188796
[TBL] [Abstract][Full Text] [Related]
17. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab.
Ahmadieh H; Moradian S; Malihi M
Int Ophthalmol; 2005; 26(4-5):191-3. PubMed ID: 17286185
[TBL] [Abstract][Full Text] [Related]
18. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
19. Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy.
Yamaji H; Shiraga F; Shiragami C; Nomoto H; Fujita T; Fukuda K
Arch Ophthalmol; 2011 Jan; 129(1):106-7. PubMed ID: 21220639
[No Abstract] [Full Text] [Related]
20. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab.
Bakri SJ; Donaldson MJ; Link TP
Eye (Lond); 2006 Dec; 20(12):1474-5. PubMed ID: 16680105
[No Abstract] [Full Text] [Related]
[Next] [New Search]
